Guobang Pharma Ltd (605507) - Total Liabilities
Based on the latest financial reports, Guobang Pharma Ltd (605507) has total liabilities worth CN¥2.68 Billion CNY (≈ $392.18 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Guobang Pharma Ltd - Total Liabilities Trend (2017–2025)
This chart illustrates how Guobang Pharma Ltd's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Guobang Pharma Ltd to evaluate short-term liquidity relative to the company's equity base.
Guobang Pharma Ltd Competitors by Total Liabilities
The table below lists competitors of Guobang Pharma Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hunan Friendship&Apollo Commercial Co Ltd
SHE:002277
|
China | CN¥7.54 Billion |
|
Guild Holdings Co
NYSE:GHLD
|
USA | $3.86 Billion |
|
Goldsun Building Materials Co Ltd
TW:2504
|
Taiwan | NT$17.84 Billion |
|
Aotecar New Energy Technology Co Ltd
SHE:002239
|
China | CN¥4.97 Billion |
|
Karooooo Ltd
JSE:KRO
|
South Africa | ZAC2.47 Billion |
|
Zhejiang Xinhua Chemical Co Ltd
SHG:603867
|
China | CN¥1.67 Billion |
|
Flow Traders BV
AS:FLOW
|
Netherlands | €15.08 Billion |
|
Yuhuan CNC Machine Tool Co Ltd
SHE:002903
|
China | CN¥363.51 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Guobang Pharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Guobang Pharma Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guobang Pharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guobang Pharma Ltd (2017–2025)
The table below shows the annual total liabilities of Guobang Pharma Ltd from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.43 Billion ≈ $355.45 Million |
-10.97% |
| 2024-12-31 | CN¥2.73 Billion ≈ $399.25 Million |
-6.70% |
| 2023-12-31 | CN¥2.92 Billion ≈ $427.94 Million |
+54.85% |
| 2022-12-31 | CN¥1.89 Billion ≈ $276.36 Million |
+61.78% |
| 2021-12-31 | CN¥1.17 Billion ≈ $170.82 Million |
-47.75% |
| 2020-12-31 | CN¥2.23 Billion ≈ $326.97 Million |
+4.24% |
| 2019-12-31 | CN¥2.14 Billion ≈ $313.67 Million |
+20.79% |
| 2018-12-31 | CN¥1.77 Billion ≈ $259.67 Million |
-2.33% |
| 2017-12-31 | CN¥1.82 Billion ≈ $265.86 Million |
-- |
About Guobang Pharma Ltd
Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives.… Read more